Can Nearly Half of Dementia Cases Be Prevented? What the Research Actually Shows

The possibility of developing dementia worries many people, particularly those who have watched a parent or grandparent lose memory, independence, and the ability to recognize the people closest to them. Genetics can make that concern feel even more immediate.

A September 2026 JAMA Medical News review offers a more hopeful view. It examines growing evidence that cardiovascular health, metabolic disease, hearing, vision, sleep, physical activity, social connection, and other modifiable factors influence cognitive aging. The article draws particular attention to the 2024 Lancet Commission estimate that as many as 45% of dementia cases worldwide could potentially be delayed or prevented.

That estimate deserves attention, but it does not mean that nearly half of individual dementia cases can be reliably stopped. The research supports a more measured conclusion: dementia is not entirely preventable, yet there are meaningful opportunities to reduce risk and protect cognitive function throughout life.

What Does “45% of Dementia Cases May Be Preventable” Actually Mean?

The figure comes from the 2024 report of the Lancet standing Commission on dementia. The Commission reviewed evidence involving 14 potentially modifiable risk factors and calculated their population-attributable fractions.

A population-attributable fraction estimates how much disease might be avoided if a risk factor were removed from a population, assuming that the observed relationship is causal and that other conditions remain comparable. It is not a measurement of how much risk a particular person can eliminate.

Several limitations are important:

• Many of the underlying relationships come from observational research.
• Associated risk factors do not always directly cause dementia.
• The risk factors overlap and frequently occur together.
• Some exposures cannot be completely eliminated.
• The relative importance of each factor varies by age, health history, genetics, and type of dementia.
• Preventing, delaying, and reducing dementia are related but different outcomes.

The estimate should therefore be treated as an indication of substantial public-health opportunity. It should not be presented as proof that 45% of dementia is individually preventable.

The 14 Modifiable Risk Factors

The Lancet Commission identified the following factors across different periods of life:

• Limited education
• Hearing loss
• Elevated LDL cholesterol
• Depression
• Traumatic brain injury
• Physical inactivity
• Diabetes
• Smoking
• Hypertension
• Obesity
• Excessive alcohol consumption
• Social isolation
• Air pollution
• Untreated vision loss

This list extends well beyond diet and exercise. It includes vascular disease, metabolic dysfunction, sensory impairment, mental health, environmental exposure, injury, and social circumstances.

Some factors may contribute through more than one pathway. Hearing loss, for example, may increase the cognitive effort required to follow conversation, reduce social participation, and reflect other age-related changes. Diabetes can affect small blood vessels, inflammation, oxidative stress, and insulin signaling. Smoking contributes to atherosclerosis, stroke risk, and vascular injury.

The list also helps explain why an effective cognitive-longevity strategy cannot be reduced to a supplement regimen or a single laboratory result.

The Brain Is Part of the Vascular System

The brain depends on a continuous supply of oxygen and nutrients delivered through an extensive network of blood vessels. Hypertension, diabetes, smoking, atherosclerosis, and previous stroke can damage that network. Vascular injury may contribute directly to vascular cognitive impairment and can coexist with Alzheimer pathology.

A 2026 observational study followed approximately 12,000 adults who were free of dementia at an average baseline age of 56. Researchers examined three readily identifiable midlife risks: hypertension, diabetes, and current smoking.

Participants with none of the three factors had an estimated 30.1 dementia-free survival years between ages 55 and 95. Those with all three had approximately 17.5 years. The study does not prove that correcting the three factors will add a specific number of dementia-free years to an individual life. It does show how strongly accumulated vascular risk in midlife is associated with both dementia and earlier death.

This relationship is discussed more fully in our articles on heart disease and dementia, ApoB and cognitive longevity, and brain insulin resistance.

Blood-Pressure Treatment Has Some of the Strongest Evidence

Hypertension is one of the clearest clinical targets because it is measurable, common, and treatable. Evidence now extends beyond observational associations.

CRHCP-3

The China Rural Hypertension Control Project Phase 3 included nearly 34,000 adults aged 40 or older with uncontrolled hypertension. Communities were randomly assigned to an intensive intervention or usual care.

The intervention used trained community health workers, medication management, home monitoring, and health coaching. Its blood-pressure goal was below 130/80 mm Hg. After four years, the intensive group had a 15% lower risk of all-cause dementia and a 16% lower risk of cognitive impairment without dementia.

Because the intervention included medication, monitoring, and lifestyle support, the study cannot determine how much of the benefit came from each component. It nevertheless provides randomized evidence that more effective hypertension management can reduce clinically meaningful cognitive outcomes.

SPRINT MIND

The SPRINT MIND trial compared an intensive systolic blood-pressure target below 120 mm Hg with a standard target below 140 mm Hg in adults with hypertension.

Intensive treatment significantly reduced the incidence of mild cognitive impairment. The reduction in probable dementia did not reach statistical significance, possibly because the trial ended earlier than planned and fewer dementia cases occurred than anticipated.

These studies do not establish one ideal blood-pressure target for every patient. Age, medication tolerance, orthostatic symptoms, kidney function, frailty, and other medical conditions remain relevant. They do establish that untreated hypertension should not be viewed only as a future heart attack or stroke concern.

What Multidomain Lifestyle Trials Have Found

Dementia develops over many years and rarely results from one exposure. Researchers have therefore studied programs that address several risks at the same time.

The FINGER trial

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability enrolled approximately 1,260 adults between 60 and 77 who had an elevated risk of dementia. The intervention included nutrition, physical activity, cognitive training, and vascular-risk monitoring.

After two years, cognitive performance improved in both groups, but the overall improvement was greater in the structured intervention group. Repeated cognitive testing can produce practice effects, and participation in a control group may prompt healthier behavior. Even with those limitations, FINGER demonstrated that a multidomain program could influence cognitive performance in adults at increased risk.

US POINTER

The US POINTER randomized clinical trial enrolled 2,111 adults aged 60 to 79 who were sedentary, had suboptimal dietary patterns, and had additional risk factors for cognitive decline.

Both groups participated in interventions involving physical activity, nutrition, cognitive and social activity, and health monitoring. The structured program provided more frequent meetings, supervised exercise, and greater accountability. Global cognition improved in both groups, with a modest additional benefit in the structured group.

The study lasted two years. It did not establish that the intervention prevents Alzheimer disease or reduces lifetime dementia incidence. Its findings support structured risk reduction while longer follow-up continues.

The trials also challenge the assumption that one unusually strict diet, one exercise modality, or one cognitive-training program holds the answer. The interventions combined ordinary health behaviors and risk-factor management, delivered consistently and with support.

Why the Weight-Loss Findings Require Careful Interpretation

Long-term findings from the Look AHEAD trial add an important complication. The original trial studied an intensive lifestyle weight-loss intervention in adults with type 2 diabetes.

During extended follow-up, the cognitive results differed according to participants’ baseline body mass index. Cognitive impairment was less common among participants who were overweight at baseline, unchanged among many of those with obesity, and more common among the group with the greatest obesity who had received the intensive intervention.

The difference did not appear to correspond to the amount or pattern of weight loss. The findings therefore do not establish that intentional weight loss damaged cognition, nor do they show that obesity protects the brain.

Weight and cognition are especially difficult to study later in life because unintentional weight loss can begin during the long preclinical period before dementia is diagnosed. Changes in smell, taste, motivation, appetite, food preparation, and daily function can all influence weight. Frailty and loss of muscle may also be hidden within a falling number on the scale.

For older adults, weight management should be evaluated alongside metabolic health, strength, nutritional adequacy, physical function, and body composition. Our discussion of cognitive function and longevity places these factors within a broader clinical context.

Sleep, Hearing, Vision, and Social Health Belong in the Evaluation

Several important dementia risks can be missed during a conventional cardiovascular or laboratory review.

Hearing and vision loss may gradually reduce a person’s participation in conversation, reading, travel, exercise, and community life. Depression can affect sleep, appetite, activity, attention, and social engagement. Isolation may develop after retirement, bereavement, illness, relocation, or loss of mobility.

Sleep disorders deserve similar attention. Poor sleep can impair concentration and memory even in the absence of neurodegenerative disease. Obstructive sleep apnea is associated with hypertension, atrial fibrillation, stroke, insulin resistance, and cognitive impairment. Symptoms and risk factors should lead to appropriate clinical evaluation rather than an assumption that fatigue or forgetfulness is simply part of aging. Read more in Obstructive Sleep Apnea, Brain Health and Longevity.

Genetics Changes Risk, Not Certainty

The APOE ε4 allele is the most important common genetic risk factor for sporadic Alzheimer disease. One or two copies can increase risk, but an APOE result does not determine whether a person will develop dementia or when it might occur.

Genetic information can also have emotional, medical, privacy, and insurance implications. Testing is most useful when the reason for ordering it, the possible results, and the clinical response have been considered in advance.

Blood tests for Alzheimer-related biomarkers are becoming more clinically useful, particularly in the evaluation of people who already have objective cognitive symptoms. Their role in cognitively normal adults remains more limited.

A positive amyloid-related blood test does not establish the timing or certainty of future dementia. A negative result does not assess every cause of cognitive decline. Broad screening also raises a practical question: what will be done differently because of the result?

The same principle applies to advanced imaging, biological-age reports, extensive laboratory panels, and genetic profiles. Testing should have a defined clinical purpose and a plan for normal, borderline, and abnormal findings.

There Is No Single Dementia-Prevention Protocol

Dementia is an umbrella term that includes Alzheimer disease, vascular dementia, Lewy body dementia, frontotemporal dementia, and mixed conditions. The relative contribution of genetics, amyloid, tau, vascular injury, metabolic disease, inflammation, sleep disruption, medication effects, depression, and other conditions differs among individuals.

Supplements have not been shown to prevent nearly half of dementia cases. Neither has one diet, one laboratory panel, one prescription, or one commercial cognitive program.

Nutrition, exercise, sleep, and selected supplements may still be useful parts of care. Their role depends on the patient’s nutritional status, medical history, medications, laboratory findings, symptoms, and overall plan. Treating a deficiency is different from selling a generalized “brain health” formula to every adult concerned about memory.

What a Clinical Approach to Cognitive Longevity Looks Like

A clinically useful evaluation begins with the person rather than a predetermined protocol. Relevant areas may include:

• Personal and family history of cognitive impairment, stroke, and cardiovascular disease
• Blood pressure, including treatment response and medication tolerance
• Glucose regulation, diabetes risk, and insulin resistance
• LDL cholesterol, ApoB, lipoprotein(a), and overall vascular risk
• Smoking, alcohol exposure, and medication review
• Sleep quality and possible sleep apnea
• Hearing and vision
• Depression, chronic stress, and social connection
• Physical activity, aerobic fitness, strength, and balance
• Body composition, visceral fat, and changes in lean mass
• Dietary pattern and nutritional adequacy
• Previous concussion or traumatic brain injury
• Baseline cognitive performance and meaningful change over time

Objective cognitive testing can provide a baseline, but one score should not be interpreted in isolation. Sleep deprivation, anxiety, depression, pain, medication effects, illness, language, education, and unfamiliarity with testing can all affect performance. Trends and clinical context are usually more informative than a single result.

The HormoneSynergy® Optimal Aging Assessment integrates cognitive screening with cardiovascular risk, metabolic health, body composition, bone health, hormones, medical history, and physician review. This broader structure is intended to identify findings that can change a patient’s plan rather than produce an isolated collection of numbers.

When Should Cognitive Symptoms Be Evaluated?

Occasional difficulty recalling a name or walking into a room and forgetting the reason can occur with normal aging, stress, distraction, or poor sleep. Evaluation becomes more important when changes are persistent, progressive, noticed by other people, or interfering with familiar responsibilities.

Examples include:

• Repeating the same questions or conversations
• Difficulty managing medication, finances, appointments, or familiar technology
• Getting lost in familiar places
• New problems with judgment, language, or personality
• Declining performance at work or in established activities
• Loss of independence in everyday tasks

Sudden confusion, new weakness, facial drooping, speech difficulty, severe headache, loss of balance, or an abrupt change in mental status requires urgent medical attention.

A More Accurate Understanding of Prevention

The current evidence does not support telling patients that nearly half of dementia can be prevented with certainty. It does support treating cognitive health as an active part of preventive medicine.

Some risks can be reduced. Others can be treated, accommodated, or monitored. Many of the most important steps begin years before memory symptoms appear. They also reduce the risk of heart attack, stroke, disability, diabetes complications, and loss of physical independence.

That is the practical significance of the 45% estimate. It identifies a large area in which better medical care, public health, and everyday living may delay cognitive decline or reduce the number of people who eventually develop dementia. It also leaves room for the biological uncertainty that remains.

Frequently Asked Questions

Can dementia really be prevented?

Not every case can be prevented. Research suggests that a substantial proportion of dementia may be delayed or avoided at the population level by addressing modifiable risks. An individual outcome cannot be guaranteed.

What is the most important modifiable dementia risk factor?

There is no single factor that applies equally to everyone. Hypertension has particularly strong evidence because randomized trials have shown that improved blood-pressure control can reduce mild cognitive impairment and, in one large trial, all-cause dementia.

Does having an APOE ε4 allele mean I will develop Alzheimer disease?

No. APOE ε4 increases susceptibility but does not determine an individual outcome. Age, vascular health, metabolic health, other genes, and environmental exposures also contribute.

Should a healthy person get an Alzheimer blood biomarker test?

Routine testing of cognitively normal adults remains an evolving area. Before testing, patients and clinicians should consider what the possible results would mean, whether confirmation would be required, and how the result would change care.

Do lifestyle programs prevent Alzheimer disease?

Multidomain programs have produced modest improvements in cognitive performance among older adults at increased risk. Researchers have not yet established how much these programs reduce the lifetime incidence of Alzheimer disease or other dementias.

Sources

1. Rubin R. Nearly Half of Dementia Cases May Be Preventable: Here’s What the Research Says So Far. JAMA. Published online September 4, 2026.
2. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404:572-628.
3. Hu J, et al. Midlife Vascular Risk Burden and Dementia-Free Survival From Age 55 to 95 Years. Neurology Open Access. 2026.
4. He J, Zhao X, Muntner P, et al. Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension. Nature Medicine. 2025.
5. Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019;321:553-561.
6. Baker LD, Espeland MA, Whitmer RA, et al. Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA. 2025.

This article is for educational purposes and is not a substitute for individualized medical advice, diagnosis, or treatment. Cognitive symptoms, cardiovascular risks, medication decisions, and genetic or biomarker testing should be discussed with an appropriately qualified healthcare professional.